A UCSF-led study found that all 46 patients given a long-acting combination of lenacapavir and cabotegravir either reached or maintained viral suppression. Median follow-up was about 100 weeks.

Nearly three-quarters of the patients had drug resistance. Those who started with detectable virus were suppressed within 13 weeks. The results were published in JAMA Network Open. Dr. Monica Gandhi is the senior author.

The combination is used off-label and is not approved. Researchers say two trials are planned. Currently, cabotegravir plus rilpivirine is the only approved long-acting regimen.